[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ptc Therapeutics (PTCT)

Ptc Therapeutics (PTCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,401,717
  • Shares Outstanding, K 82,912
  • Annual Sales, $ 1,731 M
  • Annual Income, $ 682,640 K
  • EBIT $ 892 M
  • EBITDA $ 914 M
  • 60-Month Beta 0.53
  • Price/Sales 3.12
  • Price/Cash Flow 7.41
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 64.74% (-2.54%)
  • Historical Volatility 39.80%
  • IV Percentile 84%
  • IV Rank 36.37%
  • IV High 114.22% on 05/02/25
  • IV Low 36.45% on 01/21/26
  • Expected Move (DTE 11) 5.70 (8.74%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 33
  • Volume Avg (30-Day) 126
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 9,847
  • Open Int (30-Day) 10,133
  • Expected Range 59.46 to 70.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.31
  • Number of Estimates 7
  • High Estimate $-0.04
  • Low Estimate $-0.44
  • Prior Year $10.04
  • Growth Rate Est. (year over year) -103.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.18 +3.12%
on 05/01/26
73.79 -11.71%
on 04/14/26
-3.60 (-5.24%)
since 04/01/26
3-Month
61.43 +6.06%
on 03/06/26
76.99 -15.38%
on 02/03/26
-10.38 (-13.74%)
since 01/30/26
52-Week
35.95 +81.22%
on 05/06/25
87.50 -25.54%
on 11/26/25
+15.63 (+31.56%)
since 05/01/25

Most Recent Stories

More News
PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose -

PTCT : 65.15 (+0.14%)
PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study

WARREN, N.J. , April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call today, April 28 at 4:30 p.m. ET to share results from the 24-month interim...

PTCT : 65.15 (+0.14%)
PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026

WARREN, N.J. , April 22, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2026 financial...

PTCT : 65.15 (+0.14%)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J. , April 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2026, the company approved non-statutory stock options to purchase an aggregate...

PTCT : 65.15 (+0.14%)
PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors

WARREN, N.J. , March 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the appointment of Jessica Chutter to its Board of Directors. Ms. Chutter is a highly accomplished...

PTCT : 65.15 (+0.14%)
PTC Therapeutics to Participate at Upcoming Investor Conferences

WARREN, N.J. , Feb. 23, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:

PTCT : 65.15 (+0.14%)
PTC Therapeutics: Q4 Earnings Snapshot

PTC Therapeutics: Q4 Earnings Snapshot

PTCT : 65.15 (+0.14%)
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

– Full-year 2025 product and royalty revenue of $831M, exceeding guidance –

PTCT : 65.15 (+0.14%)
PTC Therapeutics Provides Regulatory Update on Translarnaâ„¢

WARREN, N.J. , Feb. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application (NDA) resubmission for Translarna™ (ataluren)...

PTCT : 65.15 (+0.14%)
PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026

WARREN, N.J. , Feb. 5, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its fourth quarter and full year...

PTCT : 65.15 (+0.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.

See More

Key Turning Points

3rd Resistance Point 71.43
2nd Resistance Point 69.38
1st Resistance Point 67.27
Last Price 65.15
1st Support Level 63.11
2nd Support Level 61.06
3rd Support Level 58.95

See More

52-Week High 87.50
Fibonacci 61.8% 67.81
Last Price 65.15
Fibonacci 50% 61.72
Fibonacci 38.2% 55.64
52-Week Low 35.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.